logo
logo

Intrance Medical Systems Raises $8 Million To Support Development Of Its Innovative Therapy For Advanced Parkinson’S Disease

Sep 20, 2021•almost 4 years ago

Amount Raised

$8 Million

Stockholm

Description

Intrance Medical Systems Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced the company has secured USD $8 million from prominent Swedish real estate investor Erik Selin through his private company, Erik Selin Fastigheter AB. Mr. Selin has agreed to become the anchor investor as part of a Series A financing round of USD $15 million, becoming the largest shareholder next to the founders.

Company Information

Company

Intrance Medical Systems

Location

Stockholm, Stockholm County, Sweden

About

Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, is a private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, South America, Japan and Taiwan. Intrance’s lead product, known as Lecigon® in the Nordic countries and certain European markets, is a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The company is planning to advance its U.S. clinical development program in this target indication and recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). For more information, visit intrancemedical.com.